MedTrace Logo

Effect of GSK1160724 In Healthy Volunteers

NCT00555022 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-09-08

No results posted yet for this study

Summary

GSK1160724 is a potent mAChR antagonist, which is being developed for treatment of chronic obstructive pulmonary disease (COPD)

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK1160724

GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.

DRUG

Tiotropium bromide

Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.

DRUG

Placebo

Subjects will receive placebo.

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-12-12
Primary Completion
2008-04-07
Completion
2008-04-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00555022 on ClinicalTrials.gov